



FIGURE 10.33

Staurosporine-related PKC modulators in clinical trials.

the induction of VEGF-stimulated neo-angiogenesis. Ruboxistaurin is under clinical study for the treatment of microvascular complications of diabetes,²¹² and enzastaurin underwent a phase III study for recurrent malignant glioblastomas. This trial concluded that although it is well tolerated and has a good hematologic toxicity profile, its efficacy is not superior to that of lomustine,²¹³ and its development as an anticancer agent was halted in 2013. Sotrastaurin (AEB071), an immunosuppressant that blocks early T-lymphocyte (T-cell) activation via PKC inhibition,²¹⁴ may be a therapeutic option for psoriasis and has entered phase I trials for metastatic uveal melanoma.